Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-07-17

Study Completion Date

2019-10-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This protocol corresponds to a multicenter, open-label, non-randomized, phase I study designed to determine the safety of the combination of selinexor with chemotherapy in young patients with relapsed or refractory AML.

The clinical trial is divided into pre-treatment, treatment (induction and consolidation cycles) and follow-up periods and consists of a phase I design in which es-calating doses of selinexor will be given to 3 groups, each with 3-6 patients until achieving the maximum tolerated dose (MTD).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia

NCT03071276

Acute Myeloid Leukemia (AML)

TERMINATED PHASE2

A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

NCT02249091

Acute Myeloid Leukemia (Relapsed/Refractory)

COMPLETED PHASE2

Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients

NCT05951855

Acute Myeloid Leukemia (Relapsed/Refractory)

UNKNOWN PHASE2

Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

NCT02212561

Acute Myeloid Leukemia (AML) Acute Lymphoblastic Leukemia (ALL) Myelodysplastic Syndrome (MDS) +1 more

COMPLETED PHASE1

Selinexor (KPT-330) in Older Patients With Relapsed AML

NCT02088541

Acute Myeloid Leukemia (AML)

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Design:

This protocol corresponds to a multicenter, open-label, non-randomized, phase I study designed to determine the safety of the combination of selinexor with chemotherapy in young patients with relapsed or refractory AML.

The clinical trial is divided into pre-treatment, treatment (induction and consolidation cycles) and follow-up periods and consists of a phase I design in which es-calating doses of selinexor will be given to 3 groups, each with 3-6 patients until achieving the maximum tolerated dose (MTD).

Each cycle (second induction, consolidation or maintenance) of treatment will compromise 3 weeks of selinexor treatment, and at least one week off treatment. The new cycle will not start if there is an ongoing grade 3 or higher non-hematologic toxicity or persistent grade 3 neutropenia in patients achieving CR.

Study design allows a maximum of 18 patients.

Induction cycle (up to 2 cycles):

Treatment will consist of fludarabine 30 mg/m2/day intravenously on days 1 to 4, idarubicin 10 mg/m2/day intravenously on days 1 to 3, cytarabine 2 g/m2/day intravenously on days 1 to 4, G-CSF 300 mcg/m2/day subcutaneously from days -1 to 5. This schedule will be combined with oral selinexor (KPT-330) for three weeks at days and dose according to escalation level:

* Level -1: Selinexor 40 mg/day, once weekly
* Level 1: Selinexor 60 mg/day, once weekly
* Level 2: Selinexor 80 mg/day, once weekly
* Level 3: Selinexor 100 mg/day, once weekly If a partial response is obtained after the first cycle of treatment, an identical induction therapy will be administered.

If a patient achieves a complete remission after 1 or 2 cycles of FLAG-IDA plus selinexor, allogeneic stem cell transplantation (Allo-SCT) will be attempted. If Allo-SCT is not possible, this patient will receive consolidation treatment as described below.

Consolidation cycle (up to 2 cycles):

Treatment will consist of cytarabine 1 g/m2/day intravenously (3 hours) on days 1 to 6. This schedule will be combined with oral selinexor (the same dosage that was administered to the patient in the induction cycle).

At most, patients will receive up to 4 cycles of combined chemotherapy.

Maintenance cycle:

For patients in CR, and when an Allo-SCT is not feasible, a maintenance treatment with selinexor could be started for up to 6 cycles.

Selinexor will be given at the same level as during induction therapy in cycles of four weeks (3 weeks on selinexor and 1 week off).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myeloid Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fludarabine-Idarubicine-Cytarabine- Selinexor

fludarabine 30 mg/m2/day intravenously on days 1 to 4, idarubicin 10 mg/m2/day intravenously on days 1 to 3, cytarabine 2 g/m2/day intravenously on days 1 to 4, G-CSF 300 mcg/m2/day subcutaneously from days -1 to 5. This schedule will be combined with oral selinexor (KPT-330) for three weeks at days and dose according to escalation level:

* Level -1: Selinexor 40 mg/day, once weekly
* Level 1: Selinexor 60 mg/day, once weekly
* Level 2: Selinexor 80 mg/day, once weekly
* Level 3: Selinexor 100 mg/day, once weekly

Group Type EXPERIMENTAL

Selinexor

Intervention Type DRUG

According to escalation level:

* Level -1: Selinexor 40 mg/day, once weekly
* Level 1: Selinexor 60 mg/day, once weekly
* Level 2: Selinexor 80 mg/day, once weekly
* Level 3: Selinexor 100 mg/day, once weekly

fludarabine

Intervention Type DRUG

fludarabine 30 mg/m2/day intravenously on days 1 to 4

idarubicin

Intervention Type DRUG

idarubicin 10 mg/m2/day intravenously on days 1 to 3

cytarabine

Intervention Type DRUG

cytarabine 2 g/m2/day intravenously on days 1 to 4

G-CSF

Intervention Type DRUG

G-CSF 300 mcg/m2/day subcutaneously from days -1 to 5

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Selinexor

According to escalation level:

* Level -1: Selinexor 40 mg/day, once weekly
* Level 1: Selinexor 60 mg/day, once weekly
* Level 2: Selinexor 80 mg/day, once weekly
* Level 3: Selinexor 100 mg/day, once weekly

Intervention Type DRUG

fludarabine

fludarabine 30 mg/m2/day intravenously on days 1 to 4

Intervention Type DRUG

idarubicin

idarubicin 10 mg/m2/day intravenously on days 1 to 3

Intervention Type DRUG

cytarabine

cytarabine 2 g/m2/day intravenously on days 1 to 4

Intervention Type DRUG

G-CSF

G-CSF 300 mcg/m2/day subcutaneously from days -1 to 5

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent in accordance with national, local, and institutional guidelines. The patient must provide informed consent prior to the first screening procedure.
* Age ≥ 18, and ≤ 65 years old.
* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
* Diagnosis of AML (defined using WHO criteria) of any type except for acute promyelocytic leukemia (APL; AML M3).
* Relapsing or refractory AML, defined as either:

Recurrence of disease after first CR (duration of CR ≤ 24 months), or Failure to achieve CR or CRi after 1 or 2 identical induction cycles containing an anthracycline plus cytarabine based schedule.

* No contraindications to receive intensive chemotherapy.
* Female patients of child-bearing potential must have a negative serum pregnancy test at screening and agree to use two reliable methods of contraception for three months after their last dose of medication. Male patients must use a reliable method of contraception (if sexually active with a female of child-bearing potential).
* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures.

Exclusion Criteria

* Patients with APL/AML M3.
* Patients who are pregnant or lactating.
* Radiation, chemotherapy, or immunotherapy or any other anticancer therapy ≤ 2 weeks prior to Cycle 1 Day 1 or radio-immunotherapy 4 weeks prior to Cycle 1 Day 1. Hydroxyurea is permitted until 1 day prior to Cycle 1 Day 1.
* Previous treatment with a SINE compound.
* Major surgery within 2 weeks of first dose of study drug.
* Any life-threatening illness, medical condition or organ system dysfunction which, in the Investigator's opinion, could compromise the patient's safety.
* Unstable cardiovascular function:

* Symptomatic ischemia, or uncontrolled clinically significant conduction abnormalities (i.e., ventricular tachycardia on anti-arrhythmia are excluded; 1st degree AV block or asymptomatic LAFB/RBBB will not be excluded), or congestive heart failure (CHF) of NYHA Class ≥ 3, or myocardial infarction (MI) within 3 months.
* Uncontrolled (i.e., clinically unstable) infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose; however, prophylactic use of these agents is acceptable even if parenteral.
* Active hepatitis B or hepatitis C infection.
* Known human immunodeficiency virus (HIV) infection (HIV testing is not required as part of this study).
* Patients unable to swallow tablets, patients with malabsorption syndrome, or any other gastrointestinal (GI) disease or GI dysfunction that could interfere with absorption of study treatment.
* Any of the following laboratory abnormalities unless due to leukemia:

* Hepatic dysfunction: bilirubin \> 2.0 times the upper limit of normal (ULN) (except patients with Gilbert's syndrome: total bilirubin of \> 3 x ULN) and alanine aminotransferase (ALT) and aspartic aminotransferase (AST) \> 2.5 times ULN or in case of liver metastases: In patients with known liver involvement of their cancer, AST and ALT \> 5 x ULN.
* Severe renal dysfunction: estimated creatinine clearance of \< 30 mL/min, measured in 24 hour urine or calculated using the formula of Cockroft and Gault: (140-Age) x Mass (kg)/\[72 x creatinine (mg/dL)\]; multiply by 0.85 if female

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No